Cargando…
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies with a 5-year survival rate of <7%. Due to growing incidence, late diagnosis and insufficient treatment options, PDAC is predicted to soon become one of the leading causes of cancer-related death. Although...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256386/ https://www.ncbi.nlm.nih.gov/pubmed/27811314 http://dx.doi.org/10.1136/gutjnl-2016-312539 |